Treatment Results in Patients with Drug Resistant Tuberculosis (MDR, pre-XDR, XDR) and HIV Infection in Stavropol Region

Q4 Medicine

Tuberculosis and Lung Diseases Pub Date : 2024-07-05 DOI:10.58838/2075-1230-2024-102-3-64-70

N. A. Sosova, T. A. Zadremaylova, N. M. Konovalova, A. Abramchenko, M. I. Romanova, A. I. Gayda, A. G. Samoylova

{"title":"Treatment Results in Patients with Drug Resistant Tuberculosis (MDR, pre-XDR, XDR) and HIV Infection in Stavropol Region","authors":"N. A. Sosova, T. A. Zadremaylova, N. M. Konovalova, A. Abramchenko, M. I. Romanova, A. I. Gayda, A. G. Samoylova","doi":"10.58838/2075-1230-2024-102-3-64-70","DOIUrl":null,"url":null,"abstract":"The objective: to compare treatment effectiveness of drug resistant tuberculosis (MDR, pre-XDR, XDR) depending on the HIV status of patients in Stavropol Region from 2019 to 2022.Subjects and Methods. In a retrospective study, chemotherapy outcomes for pulmonary tuberculosis (TB) were evaluated with distribution by treatment regimens for MDR, pre-XDR, and XDR in 100 patients with drug resistant tuberculosis (MDR, pre-XDR, XDR and HIV infection (DR TB/HIV Group ) and 707 patients with drug resistant tuberculosis (MDR, pre-XDR, and XDR) (and negative HIV status (DR TB Group). The immune status of patients in DR TB/HIV Group and its impact on the effectiveness of tuberculosis treatment were analyzed.Results. Effective treatment (definitions are given according to the Guidelines) was statistically significantly more frequently registered in DR TB Group versus DR TB/HIV Group (59% and 48%, respectively, p<0.05). Treatment failure was statistically significantly more frequently registered in patients in DR TB/HIV Group versus DR TB Group (42% and 26%, respectively, p<0.05). In DR TB/HIV Group, the lowest effectiveness (33%) of tuberculosis treatment was noted in the patients with CD4 count below 200 cells/µL. Among those died, the median time to death from the start of tuberculosis treatment was 12 months in DR TB Group, 8 months in DR TB/HIV Group, and 4 months in the subgroup of patients with CD4 count below 100 cells/µL.","PeriodicalId":37828,"journal":{"name":"Tuberculosis and Lung Diseases","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tuberculosis and Lung Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.58838/2075-1230-2024-102-3-64-70","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

The objective: to compare treatment effectiveness of drug resistant tuberculosis (MDR, pre-XDR, XDR) depending on the HIV status of patients in Stavropol Region from 2019 to 2022.Subjects and Methods. In a retrospective study, chemotherapy outcomes for pulmonary tuberculosis (TB) were evaluated with distribution by treatment regimens for MDR, pre-XDR, and XDR in 100 patients with drug resistant tuberculosis (MDR, pre-XDR, XDR and HIV infection (DR TB/HIV Group ) and 707 patients with drug resistant tuberculosis (MDR, pre-XDR, and XDR) (and negative HIV status (DR TB Group). The immune status of patients in DR TB/HIV Group and its impact on the effectiveness of tuberculosis treatment were analyzed.Results. Effective treatment (definitions are given according to the Guidelines) was statistically significantly more frequently registered in DR TB Group versus DR TB/HIV Group (59% and 48%, respectively, p<0.05). Treatment failure was statistically significantly more frequently registered in patients in DR TB/HIV Group versus DR TB Group (42% and 26%, respectively, p<0.05). In DR TB/HIV Group, the lowest effectiveness (33%) of tuberculosis treatment was noted in the patients with CD4 count below 200 cells/µL. Among those died, the median time to death from the start of tuberculosis treatment was 12 months in DR TB Group, 8 months in DR TB/HIV Group, and 4 months in the subgroup of patients with CD4 count below 100 cells/µL.

查看原文本刊更多论文

斯塔夫罗波尔州耐药结核病（MDR、前XDR、XDR）和艾滋病毒感染患者的治疗结果

目的：比较2019年至2022年斯塔夫罗波尔州根据患者的艾滋病毒感染状况对耐药结核病（MDR、前XDR、XDR）的治疗效果。在一项回顾性研究中，对100名耐药结核病（MDR、前XDR、XDR和HIV感染）患者（DR TB/HIV组）和707名耐药结核病（MDR、前XDR和XDR）患者（HIV阴性（DR TB组））的肺结核（TB）化疗结果进行了评估，并按MDR、前XDR和XDR治疗方案进行了分配。分析了 DR TB/HIV 组患者的免疫状况及其对结核病治疗效果的影响。据统计，DR TB 组与 DR TB/HIV 组相比，有效治疗（根据《指南》给出的定义）的比例明显更高（分别为 59% 和 48%，P<0.05）。DR TB/HIV 组与 DR TB 组相比，治疗失败的比例明显更高（分别为 42% 和 26%，P<0.05）。在 DR TB/HIV 组中，CD4 细胞计数低于 200 cells/µL 的患者的结核病治疗有效率最低（33%）。在死亡患者中，肺结核 DR TB 组从开始结核病治疗到死亡的中位时间为 12 个月，肺结核 DR TB/HIV 组为 8 个月，CD4 细胞数低于 100 个/µL 的亚组患者为 4 个月。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Tuberculosis and Lung Diseases Medicine-Pulmonary and Respiratory Medicine

CiteScore

1.20

自引率

0.00%

发文量

审稿时长

8 weeks

期刊介绍： The Journal is aimed for professional development of researchers, doctors, teachers of medical universities and training institutions. The Journal focuses on the presentation of results of research, case studies, issues of differential diagnostics and treatment in the phthisiologist’s practice, national programs on tuberculosis control in the Russian Federation, WHO strategies, discussion of prevention issues to stop transmission of TB/HIVco-infection, and extrapulmonary tuberculosis.